Patents by Inventor Viktoria Gusarova
Viktoria Gusarova has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Publication number: 20190315851Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: ApplicationFiled: June 7, 2019Publication date: October 17, 2019Inventors: Mark W. SLEEMAN, Viktoria GUSAROVA, Andrew J. MURPHY
-
Patent number: 10442856Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the invention includes methods of using anti-ANGPTL8 antibodies that bind human ANGPTL8 with high affinity to treat obesity, reduce body fat, reduce body weight, increase energy expenditure, and increase HDL-C, in a subject.Type: GrantFiled: November 17, 2017Date of Patent: October 15, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
-
Patent number: 10358487Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: GrantFiled: April 20, 2018Date of Patent: July 23, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
-
Patent number: 10259870Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.Type: GrantFiled: August 4, 2016Date of Patent: April 16, 2019Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy, David R. Buckler
-
Publication number: 20190092845Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: ApplicationFiled: April 20, 2018Publication date: March 28, 2019Inventors: MARK W. SLEEMAN, VIKTORIA GUSAROVA, ANDREW J. MURPHY
-
Publication number: 20180244801Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, this PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: ApplicationFiled: January 18, 2018Publication date: August 30, 2018Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-ludwig Schaefer, Uwe Schwahn
-
Publication number: 20180134781Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the invention includes methods of using anti-ANGPTL8 antibodies that bind human ANGPTL8 with high affinity to treat obesity, reduce body fat, reduce body weight, increase energy expenditure, and increase HDL-C, in a subject.Type: ApplicationFiled: November 17, 2017Publication date: May 17, 2018Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
-
Patent number: 9951127Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: GrantFiled: March 24, 2015Date of Patent: April 24, 2018Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
-
Publication number: 20170291937Abstract: The present invention provides methods for treating patients suffering from hyperlipidaemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to angiopoietin-like protein 8 (ANGPTL8) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3).Type: ApplicationFiled: April 7, 2017Publication date: October 12, 2017Inventors: Jesper Gromada, Viktoria Gusarova, Andrew J. Murphy
-
Publication number: 20170253666Abstract: The present invention provides methods for treating patients suffering from hypercholesterolemia, wherein the patient is non-responsive to, inadequately controlled by, or intolerant to treatment with a standard lipid modifying therapy. The methods of the invention provide for lowering at least one lipid parameter in the patient by administering a therapeutically effective amount of an antibody or antigen-binding fragment thereof that specifically binds to proprotein convertase subtilisin/kexin type 9 (PCSK9) in combination with a therapeutically effective amount of an antibody that specifically binds to angiopoietin-like protein 3 (ANGPTL3).Type: ApplicationFiled: March 1, 2017Publication date: September 7, 2017Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy
-
Publication number: 20170245481Abstract: Non-human animals, and methods and compositions for making and using the same, are provided, wherein said non-human animals comprise a humanization of an Angiopoietin-like protein 8 (ANGPTL8) gene. Said non-human animals may be described, in some embodiments, as having a genetic modification to an endogenous ANGPTL8 locus so that said non-human animals express a human ANGPTL8 polypeptide.Type: ApplicationFiled: February 3, 2017Publication date: August 31, 2017Inventors: Viktoria Gusarova, Andrew J. Murphy, Jesper Gromada, Dayong Guo
-
Publication number: 20170233466Abstract: The present invention provides methods and compositions for treating or preventing atherosclerosis in a subject. The methods of the present invention comprise administering an inhibitor of angiopoietin-like protein-3 (ANGPTL3) to a subject who has atherosclerosis or is at risk of developing atherosclerosis. In certain embodiments, the ANGPTL3 inhibitor is an antibody or antigen-binding fragment thereof that specifically binds ANGPTL3.Type: ApplicationFiled: February 13, 2017Publication date: August 17, 2017Inventors: Jesper Gromada, Viktoria Gusarova, Andrew J. Murphy
-
Publication number: 20170037124Abstract: The present invention provides antibodies that bind to ANGPTL8 and methods of using the same. According to certain embodiments, the antibodies of the invention bind human ANGPTL8 with high affinity. The antibodies of the invention may be fully human antibodies. The antibodies of the invention are useful for the treatment of various diseases or disorders characterized in part by elevated blood triglyceride levels.Type: ApplicationFiled: August 4, 2016Publication date: February 9, 2017Inventors: Viktoria Gusarova, Jesper Gromada, Andrew J. Murphy, David R. Buckler
-
Publication number: 20160115246Abstract: The present invention provides methods and compositions for inhibiting atherosclerotic plaque formation in a subject. In certain embodiments, the methods of the present invention comprise selecting a subject who has, or is at risk of developing, atherosclerosis, and administering to the subject a pharmaceutical composition comprising a proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor. In certain embodiments, the PCSK9 inhibitor is an anti-PCSK9 antibody, or antigen binding protein.Type: ApplicationFiled: June 6, 2014Publication date: April 28, 2016Inventors: William J. Sasiela, Viktoria Gusarova, Anusch Peyman, Hans-ludwig Schaefer, Uwe Schwahn
-
Patent number: 9120851Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: GrantFiled: December 12, 2012Date of Patent: September 1, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Viktoria Gusarova, Jee H. Kim, Gang Chen
-
Publication number: 20150197564Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: ApplicationFiled: March 24, 2015Publication date: July 16, 2015Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
-
Patent number: 9018356Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: GrantFiled: June 14, 2012Date of Patent: April 28, 2015Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
-
Publication number: 20130266574Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: ApplicationFiled: December 12, 2012Publication date: October 10, 2013Applicant: REGENERON PHARMACEUTICALS, INC.Inventors: Mark W. SLEEMAN, Viktoria GUSAROVA, Jee H. KIM, Gang CHEN
-
Publication number: 20130171149Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits or interferes with at least one activity of human angiopoietin-like protein 3 (hANGPTL3) is provided. The human anti-hANGPTL3 antibodies are useful in treating diseases or disorders associated with ANGPTL3, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL3 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: ApplicationFiled: June 14, 2012Publication date: July 4, 2013Applicant: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Viktoria Gusarova, Andrew J. Murphy
-
Patent number: 8354103Abstract: A fully human antibody or antigen-binding fragment of a human antibody that specifically binds and inhibits human angiopoietin-like protein 4 (hANGPTL4) is provided. The human anti-hANGPTL4 antibodies are useful in treating diseases or disorders associated with ANGPTL4, such as hyperlipidemia, hyperlipoproteinemia and dyslipidemia, including hypertriglyceridemia, hypercholesterolemia, chylomicronemia, and so forth. Furthermore, the anti-hANGPTL4 antibodies can be administered to a subject in need thereof to prevent or treat diseases or disorders, for which abnormal lipid metabolism is a risk factor. Such diseases or disorders include cardiovascular diseases, such as atherosclerosis and coronary artery diseases; acute pancreatitis; nonalcoholic steatohepatitis (NASH); diabetes; obesity; and the like.Type: GrantFiled: December 23, 2010Date of Patent: January 15, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Mark W. Sleeman, Viktoria Gusarova, Jee H. Kim, Gang Chen